Deepen Scientific Understanding of Inflammatory & Fibrotic ILDs, Investigate Biomarkers to Stratify Trial Populations and Identify Endpoints Which are Likely to Predict Clinical Success in Your Next Clinical Trial
Thank you to our speakers, sponsors, and delegates who joined us for the summit! If you are interested in the 2023 event, please get in touch at firstname.lastname@example.org
2022 dawned with an exhilarating update from aTyr pharma that the FDA has granted orphan drug designation for ATYR1923 for the treatment of sarcoidosis, kickstarting the new year by giving ILD drug developers the signal that the window of therapeutic opportunity to develop clinically defining drugs to treat interstitial lung disease is well and truly open.
The timely 2nd ILD Summit is uniquely positioned to siphon critical insights from experts at Pfizer, Genentech, Novartis, Boehringer Ingelheim, Pieris Pharmaceuticals and more to help you catalyze a new wave of therapies against ILDs such as Scleroderma, Sarcoidosis, COP, CT-ILDs.
Our 2022 program has been revamped and upgraded to explore a whole host of BRAND NEW TOPICS including therapeutic strategies against fibrotic AND inflammatory ILDs, machine learning’s role in respiratory drug development and emerging therapies like anticalins!
What’s more, it has a new pre-conference day dedicated to overcoming challenges with inhaled drug delivery and biomarkers for ILD clinical trials - making this the perfect intensive crash course for experts across your team to get up to speed with the insights they need to accelerate their ILD drug development.
Join 20+ brand new speakers and 150+ drug developers from leading companies online to uncover the secrets behind developing industry defining ILD therapies, tailor the experience to meet your needs and supercharge your ILD drug development approach.
World Class Speaker Faculty Included
CEO, Chairman & Founder
Vice President & Chief Regulatory, Quality & Safety Officer
Vice President of Cancer Immunology Discovery